SCHEMBL8312704

SCHEMBL8312704

O=C(COCc1cc(S(=O)(=O)N2CCCCC2)ccc1OC(F)(F)F)c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MAPK1 P28482 1/20 0.48
RXFP1 Q9HBX9 1/20 0.47
RAB9A P51151 3/20 0.43
HTT P42858 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
POLB P06746 1/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 2/20 0.43
GAA P10253 2/20 0.42
F2 P00734 1/20 0.42
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715769 0.88 RXFP1 (0.58) ALDH1A1SMN1; SMN2MAPK1RXFP1HTT
SCHEMBL4713091 0.86 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2MAPK1RXFP1RAB9A
SCHEMBL4717827 0.85 MAPK1 (0.61) ALDH1A1SMN1; SMN2MAPK1RXFP1RAB9A
SCHEMBL5739571 0.79 SMN1; SMN2 (0.52) ALDH1A1SMN1; SMN2MAPK1RXFP1RAB9A
SCHEMBL4713578 0.78 KMT2A (0.44) ALDH1A1KMT2ACRHBPCRHR2TDP1
SCHEMBL4713822 0.77 L3MBTL1 (0.47) ALDH1A1SMN1; SMN2MAPK1RAB9ALMNA
SCHEMBL4714178 0.75 LMNA (0.57) ALDH1A1SMN1; SMN2MAPK1RXFP1LMNA
SCHEMBL4713433 0.74 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2MAPK1HTTLMNA
SCHEMBL4716756 0.73 ALDH1A1 (0.55) ALDH1A1MAPK1RAB9AKMT2AKDM4E
SCHEMBL4714606 0.73 RAB9A (0.56) ALDH1A1SMN1; SMN2MAPK1RXFP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
WO-2004092135-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA (SE) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021606-A1 Therapeutic compounds GRIN1, GRIN3A, GRM2 ALDH1A1 1721/4885SMN1; SMN2 2089/4885MAPK1 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.